Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice! Thank you for that Darth. Charlotte's Web is a trailblazer in the industry.
Just to go apples to apples, yes, the coca plant itself is also schedule 2. That goes for the opium poppy plant as well...
"§ 1308.12 Schedule II.":
(3) Opium poppy and poppy straw.
(4) Coca leaves (9040) and any salt, compound, derivative or preparation of coca leaves (including cocaine (9041) and ecgonine (9180) and their salts, isomers, derivatives and salts of isomers and derivatives), and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include:
(i) Decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine; or
(ii) [123I]ioflupane.
(5) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrene alkaloids of the opium poppy), 9670.
Pretty low bar..."a topical local anesthetic for the upper respiratory tract."...that's all...
Cocaine is a Schedule II drug under the Controlled Substances Act, meaning it has a high potential for abuse and has an accepted medical use for treatment in the United States. Cocaine hydrochloride solution (4 percent and 10 percent) is used primarily as a topical local anesthetic for the upper respiratory tract.
The extremely limited medical uses of cocaine are enough to let it be schedule 2, even with it's extremely high potential for abuse, and there are no state medical cocaine programs. 90% of U.S. states have MMJ programs. Cannabis has a similar dependence potential as caffeine, but caffeine can be lethal...
https://commons.wikimedia.org/wiki/File:Drug_danger_and_dependence.svg
The dorks bullshitted on weed for the last 2 years so they could save it as a carrot to dangle in front of voters for midterms lol. What is or is not a schedule one substance by definition should have nothing to do with who wins anything...
Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Some examples of Schedule I drugs are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote.
FDA has approved Epidiolex, which contains a purified form of the drug substance cannabidiol (CBD) for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older. That means FDA has concluded that this particular drug product is safe and effective for its intended use.
The agency also has approved Marinol and Syndros for therapeutic uses in the United States, including for nausea associated with cancer chemotherapy and for the treatment of anorexia associated with weight loss in AIDS patients. Marinol and Syndros include the active ingredient dronabinol, a synthetic delta-9- tetrahydrocannabinol (THC) which is considered the psychoactive intoxicating component of cannabis (i.e., the component responsible for the “high” people may experience from using cannabis). Another FDA-approved drug, Cesamet, contains the active ingredient nabilone, which has a chemical structure similar to THC and is synthetically derived. Cesamet, like dronabinol-containing products, is indicated for nausea associated with cancer chemotherapy.
FDA is aware that unapproved cannabis and/or unapproved cannabis-derived products are being used to treat a number of medical conditions including, AIDS wasting, epilepsy, neuropathic pain, spasticity associated with multiple sclerosis, and cancer and chemotherapy-induced nausea.
States/Territories with Medical Marijuana Laws
Alaska Alabama Arizona
Arkansas California CNMI
Colorado Connecticut Delaware
District of Columbia Florida Guam
Hawaii Illinois Louisiana
Maine Maryland Massachusetts
Michigan Minnesota Mississippi
Missouri Montana Nevada
New Hampshire New Jersey New Mexico
New York North Dakota Ohio
Oklahoma Oregon Pennsylvania
Puerto Rico Rhode Island South Dakota
Utah Vermont Virginia
Virgin Islands Washington West Virginia
Current Assignee: US Department of Health and Human Services
Status: Expired - Lifetime
Bloomberg's Shea said that if the Democrats hold a majority in Congress after the midterms, progress toward legalization is a plausible scenario followed by "a subsequent rush of equity capital markets activity."
#DDAmanda Chart on: $NWBO :
You can scan for these before they run. #DDAmanda works.
#DDAmanda Halloween Special: https://ddamanda.com/SignUpHalloween175.php
#DDAmanda is still the best way to find #WinningStocks before they run.
Contact/Text: 760 702-2009
Trial Subscription($8): https://www.ddamanda.com/SignUpDaily.php
What the Fact (Factor) Column is:
The Factor is a proprietary indicator used for scanning in #DDAmanda.
It's defined as Today's $Traded divided by the average daily $Traded (20 day avg).
SO, if a stock has say a 10 Factor that day, it means she traded 10 Times the $ she normally trades.
That's significant, and many times indicates that a run in the stock is coming.
Endexx Highlights Fiscal Fourth Quarter 2022 Accomplishments
$EDXC - Endexx Corporation reviews key accomplishments over the Company’s fiscal fourth quarter ahead of financial reporting.
Highlights include:
Blesswell™ men’s skincare line introduced first in Target stores and then on Amazon.com. Following Endexx’s CBD pain products availability at Walgreens and skincare at CVS , Endexx products are now available in four of the top eight retailers in the United States in over 8000 mass retail stores nationwide.
Amazon distribution of Blesswell™ skin care products expanded beyond the United States to 13 countries, including Australia, Belgium, Canada, France, Germany Italy, Japan, Mexico, Netherlands, Poland, Spain, Sweden, and the United Kingdom
Endexx significantly expanded its international distribution network and potential revenue streams though the controlling interest acquisition of HYLA, a non-nicotine, guarana-based vape product available in Germany, Italy, Israel, Egypt, Slovenia, Romania, Iran and Bahrain, the United States (where the HYLA formulations are produced) Canada, the Czech Republic, Georgia, Russia, Slovakia, South Africa, Switzerland, the United Arab Emirates, the United Kingdom, and Uzbekistan
Endexx strengthened its balance sheet by entering into the settlement, lock-up, and leak-out agreements with its Historic Investors, in which each Historic Investor agreed to exchange its pre-acquisition Convertible Note and Warrants with a replacement simple Promissory Note. This new Historic Investor Replacement Note removed the convertible debt and warrants and replaced by a simple, non-convertible debt facility with an 18-month term.
HYLA secured two new purchase orders exceeding 200,000 units in the first month of joining Endexx.
https://finance.yahoo.com/news/endexx-highlights-fiscal-fourth-quarter-120000947.html
Historic cannabis news!...Major League Baseball and $CWBHF...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170173327
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170175588
Canopy Growth Corporation $CGC who's buying their stock shares? https://finance.yahoo.com/quote/CGC/holders?p=CGC
Aurora Cannabis Inc. $ACB Who's buying? https://finance.yahoo.com/quote/ACB/holders?p=ACB
Sundial Growers $SNDL whos buying? https://finance.yahoo.com/quote/SNDL/holders?p=SNDL
Canopy Growth Corporation $CGC Top Institutional Holders
Holder Shares Date Reported % Out Value
Vanguard Group, Inc. (The) 8,099,679 Jun 29, 2022 1.69% 20,208,698
ETF Managers Group, LLC 7,856,049 Jun 29, 2022 1.64% 19,600,841
Millennium Management Llc 3,152,591 Jun 29, 2022 0.66% 7,865,714
Morgan Stanley 2,839,979 Jun 29, 2022 0.59% 7,085,747
Bank of America Corporation 2,057,707 Jun 29, 2022 0.43% 5,133,978
Two Sigma Investments, LP 1,862,092 Jun 29, 2022 0.39% 4,645,919
Bank of Montreal/Can/ 1,721,627 Jun 29, 2022 0.36% 4,295,459
Shaw D.E. & Co., Inc. 1,197,214 Jun 29, 2022 0.25% 2,987,048
Ameriprise Financial, Inc. 1,196,406 Jun 29, 2022 0.25% 2,985,032
Two Sigma Advisers, LP 1,157,100 Jun 29, 2022 0.24% 2,886,964
Top Mutual Fund Holders
Holder Shares Date Reported % Out Value
ETF Managers Tr-EFTMG Alternative Harvest ETF 7,856,049 Jun 29, 2022 1.64% 19,600,841
Vanguard International Stock Index-Total Intl Stock Indx 3,249,463 Jul 30, 2022 0.68% 8,107,409
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 1,772,589 Jun 29, 2022 0.37% 4,422,609
Global X Fds-The Global X Cannabis ETF 1,543,348 Aug 30, 2022 0.32% 3,850,653
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index 1,114,799 Jul 30, 2022 0.23% 2,781,423
Spinnaker ETF Tr-Cannabis ETF 489,767 May 30, 2022 0.10% 1,221,968
AdvisorShares Trust-AdvisorShares Pure Cannabis ETF 469,798 Sep 29, 2022 0.10% 1,172,145
Schwab Strategic Tr-Schwab International Small Cap Equity ETF 421,326 May 30, 2022 0.09% 1,051,208
Amplify Seymour Cannabis ETF 445,349 Jul 30, 2022 0.09% 1,111,145
DFA Investment Dimensions-Canadian Small Company Series 313,200 Jul 30, 2022 0.07% 781,433
$ACB Top Institutional Holders
Holder Shares Date Reported % Out Value
ETF Managers Group, LLC 10,526,850 Jun 29, 2022 3.50% 10,947,923
Vanguard Group, Inc. (The) 7,118,236 Jun 29, 2022 2.37% 7,402,965
Millennium Management Llc 3,274,509 Jun 29, 2022 1.09% 3,405,489
Renaissance Technologies, LLC 3,220,384 Jun 29, 2022 1.07% 3,349,199
Shaw D.E. & Co., Inc. 2,664,650 Jun 29, 2022 0.89% 2,771,235
Two Sigma Investments, LP 2,515,071 Jun 29, 2022 0.84% 2,615,673
Morgan Stanley 2,385,461 Jun 29, 2022 0.79% 2,480,879
Mirae Asset Global Investments Co., Ltd. 1,798,034 Jun 29, 2022 0.60% 1,869,955
Bank of Montreal/Can/ 1,124,549 Jun 29, 2022 0.37% 1,169,530
Dimensional Fund Advisors LP 1,021,516 Jun 29, 2022 0.34% 1,062,376
Top Mutual Fund Holders
Holder Shares Date Reported % Out Value
ETF Managers Tr-EFTMG Alternative Harvest ETF 10,526,850 Jun 29, 2022 3.50% 10,947,923
Global X Fds-The Global X Cannabis ETF 2,921,758 Aug 30, 2022 0.97% 3,038,628
Vanguard International Stock Index-Total Intl Stock Indx 2,682,478 Jul 30, 2022 0.89% 2,789,777
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 1,563,747 Jun 29, 2022 0.52% 1,626,296
DFA Investment Dimensions-Canadian Small Company Series 763,275 Jul 30, 2022 0.25% 793,805
Spinnaker ETF Tr-Cannabis ETF 408,045 May 30, 2022 0.14% 424,366
Schwab Strategic Tr-Schwab International Small Cap Equity ETF 351,932 May 30, 2022 0.12% 366,009
College Retirement Equities Fund-Stock Account 331,029 Jun 29, 2022 0.11% 344,270
Fidelity NASDAQ Composite Index Fund 266,465 Aug 30, 2022 0.09% 277,123
iShares Core MSCI Total International Stock ETF 252,412 Aug 30, 2022 0.08% 262,50
For what it's worth, it is the Federal Government's own cannabis patent, 6630507, that lead many of us industry vets into the first "pot stocks" a decade ago. If they want rescheduling to move fast now, it will, as they really should have removed it from schedule 1 status as soon as they were assigned that patent. How long do we think it will take the Department of Health and Human Services to review their own patent LOL?...Expired or not, oddly enough, the patent was granted 19 years ago from today...
"Cannabinoids as antioxidants and neuroprotectants":
US-6630507-B1
Publication Date
2003/10/07
Current Assignee
US Department of Health and Human Services
Status
Expired - Lifetime
Abstract
Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH3, and COCH3.
U.S. Health and Human Services (HHS) Secretary Xavier Becerra said in Tampa Friday that he intends for his agency to move “as quickly as we can” to comply with President Joe Biden’s directive to review the decades-old policy of listing marijuana as a Schedule I drug.
Actually..."Biden Health Secretary Has Already Talked To FDA About Marijuana Scheduling Review, Which Will Move ‘Quickly’":
October 7, 2022
https://www.marijuanamoment.net/biden-health-secretary-has-already-talked-to-fda-about-marijuana-scheduling-review-which-will-move-quickly/
Just great. So the MORE act will not be be passed anytime soon. They’re going to take their sweet ass time “investigating” why it is a schedule one drug. I can save them a bunch of time
but they already know this. It’s a schedule one because Mr. Rockefeller wanted it to be.
"Justice Department Statement on President’s Announcements Regarding Simple Possession of Marijuana":
October 6, 2022
The Justice Department today released the following statement from spokesman Anthony Coley regarding the President’s proclamation granting a full, complete, and unconditional pardon to U.S. citizens and lawful permanent residents who have committed, or been convicted of, the offense of simple possession of marijuana in violation of the Controlled Substances Act, as currently codified at 21 U.S.C. 844 and as previously codified elsewhere in the U.S. Code, or in violation of D.C. Code 48–904.01(d)(1):
“The Justice Department will expeditiously administer the President’s proclamation, which pardons individuals who engaged in simple possession of marijuana, restoring political, civil, and other rights to those convicted of that offense. In coming days, the Office of the Pardon Attorney will begin implementing a process to provide impacted individuals with certificates of pardon.
“Also, in accordance with the President’s directive, Justice Department officials will work with our colleagues at the Department of Health and Human Services as they launch a scientific review of how marijuana is scheduled under federal law.”
Here buddy, "Pelosi Statement on President Biden’s Historic Marijuana Reform":
OCTOBER 6, 2022
San Francisco — Speaker Nancy Pelosi issued this statement after President Biden announced historic marijuana reform, including pardoning of previous federal offenses of simple possession and urging governors to do the same at the state level, and ordering a review of the classification of marijuana as Schedule I drug:
“Today is a day of hope and healing, as President Biden takes historic steps to reform America’s approach to marijuana. These transformative actions are the latest manifestation of Democrats’ unyielding commitment to justice, especially for those unfairly harmed by cannabis criminalization.
“For far too long, failed federal drug policies — which have specifically targeted communities of color — have torn apart too many families. By pardoning those arrested for simple marijuana possession, and encouraging governors to follow suit, President Biden is advancing racial and economic justice: empowering more Americans to return to their loved ones, find a good-paying job and contribute to our communities. At the same time, exploring the reclassification of marijuana is a necessary step to ensure that we do not repeat the grave mistake of mass incarceration.
“House Democrats applaud these bold actions by President Biden, which build on the important progress we forged in passing our Marijuana Opportunity Reinvestment and Expungement Act. This legislation, which decriminalizes marijuana at the federal level and empowers all to participate in the rapidly growing cannabis industry, must become law. Our proud Democratic Majority will never relent in fighting for these reforms, and more, as we work to advance justice for all.”
I don't know, but here are a handful of possible lines of reasoning that could be, and any combo of them...
1.)It's close to voting time, and the left hasn't been polling well, so this is one big tool for gaining back some support.
2.)Could be the MORE Act is just too difficult to get passed.
3.)It may just be time because, as you can see in my earlier post, based on what Obama said in 2015, having "enough" states decriminalized would allow congress to reschedule cannabis, and we now have more than fifty percent of the states decriminalized...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170114569
4.)Economic boost, why wait?
5.) Could just be getting too complicated with all the conflicting laws at the state and Federal levels.
I'm sure others can add more...
Why do you think he’s not using the MORE act?
"Biden Announces Mass Marijuana Pardons And Calls For Cannabis Scheduling Review":
October 6, 2022
https://www.marijuanamoment.net/biden-announces-mass-marijuana-pardons-and-calls-for-cannabis-scheduling-review/
Here comes the move to decriminalize...
"Biden to pardon all federal offenses of simple marijuana possession in first major steps toward decriminalization":
October 6, 2022
https://www.cnn.com/2022/10/06/politics/marijuana-decriminalization-white-house-joe-biden/index.html
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170114569
A variety of sector news below...
This new paper below shows that CBD does not convert into THC in the stomach as some have suggested. This may be an important and positive finding for the industry...
"Will tetrahydrocannabinol be formed from cannabidiol in gastric fluid? An in vivo experiment":
2022 Oct 3
Abstract
Cannabidiol (CBD) products have ascribed an uprising trend for their health-promoting effects worldwide. In contrast to ?9-tetrahydrocannabinol (THC), CBD exhibits no state of euphoria. Since conversion of CBD into THC in an acidic environment has been reported, it has not been proved whether this degradation will also occur in human gastric fluid. A total of 9 subjects ingested 400 mg CBD as a water-soluble liquid together with lecithin as an emulsifier and ethanol as a solubilizer. Blood samples were taken up to 4 h, and urine samples were submitted up to 48 h. THC, 11-hydroxy-?9-THC (THC-OH), 11-nor-9-carboxy-?9-THC (THC-COOH), CBD, 7-hydroxy cannabidiol (7-OH-CBD), and 7-carboxy cannabidiol (7-CBD-COOH) were determined in blood and THC-COOH and 7-CBD-COOH in urine by LC-MS/MS. Neither THC, THC-OH, nor THC-COOH were detectable in any serum specimen. Only two urine samples revealed THC-COOH values slightly above the threshold of 10 ng/ml, which could also be caused by trace amounts of THC being present in the CBD liquid. It can be concluded that negative consequences for participants of a drug testing program due to a conversion of CBD into THC in human gastric fluid appear unlikely, especially considering a single intake of dosages of less than 400 mg. Nevertheless, there is a reasonable risk for consumers of CBD products being tested positive for THC or THC metabolites. However, this is probably not caused by CBD cyclization into THC in human gastric fluid but is most likely due to THC being present as an impurity of CBD products.
Congressman Morgan Griffith (R-VA) and Congressman Brett Guthrie (R-KY) today sent two letters to Food and Drug Administration (FDA) Commissioner Dr. Robert Califf posing questions about numerous FDA regulatory lapses and calling for answers.
One of the letters focuses on FDA’s Center for Food Safety and Applied Nutrition (CFSAN) and its failures to ensure a safe and adequate infant formula supply. That letter can be viewed here.
https://morgangriffith.house.gov/uploadedfiles/cfsan_letter_9.19.22.pdf
The other letter focuses on lapses by CFSAN and the Center for Tobacco Products regarding cannabidiol (CBD), CBD-derived products, and tobacco products. That letter can be viewed here.
https://morgangriffith.house.gov/uploadedfiles/ctp_cfsan_letter_9.19.22.pdf
Responses to both letters are requested by October 17, 2022.
A recent study by Coresight Research suggests that the marijuana market has nearly tripled over the previous three years as legalization spreads across the United States.
According to the report’s findings, 22% of the 1,017 survey participants from the 41 states (plus the District of Columbia) where marijuana is currently legal in some form reported having bought it for recreational or therapeutic purposes over the previous 12 months.
It also suggests that participants’ average monthly spending was $85; 1 in 4 spent less than $30, while 9% spent $200 or more.
As a result, Coresight projected that the market is now valued at around $64.3 billion yearly, up from $21.5 billion in 2019.
Two-thirds of marijuana users claimed that their use had grown since marijuana was legalized, 57% of those consumers claimed to have smoked it, 46% to have eaten it, and 42% to have vaped it.
Click below to learn about these races to watch:
U.S. Senate
https://www.nxtbook.com/emerald/MJBizMag/202210/index.php/44/?startid=44#/p/44
U.S. House of Representatives
https://www.nxtbook.com/emerald/MJBizMag/202210/index.php/44/?startid=48#/p/48
Some cannabis industry news links below...
"2023 Farm Bill: Potential savior for hemp-derived cannabinoids?":
Oct 05, 2022
https://www.naturalproductsinsider.com/regulatory/2023-farm-bill-potential-savior-hemp-derived-cannabinoids
More coverage on new FDA cannabis regulator...
"FDA Hires Former New York & Rhode Island Cannabis Regulator as Senior Policy Advisor":
1 hour ago
In New York, Birenbaum helped oversee the implementation of rules that allowed CBD and other hemp-derived cannabinoid products to be sold as food, beverage, and dietary supplements.
Beyond decriminalization and MMJ, we could add another 5 states with recreationally legal cannabis next month, bringing that total up to 24...
"Voters In Five States To Decide On Legalizing Weed This November":
Oct 3, 2022
This November, voters in five states—Arkansas, Maryland, Missouri, North Dakota and South Dakota—will decide on whether they want to legalize adult-use marijuana.
Currently, 19 states, comprising 44 percent of the U.S. population, have legal adult-use marijuana markets. If voters in Arkansas, Maryland, Missouri, North Dakota and South Dakota approve adult-use, about half of the U.S. population will reside in a jurisdiction where the possession and use of cannabis are legal for adults.
I remember what Barry said in 2015..."if enough states end up decriminalizing"...
Medical Marijuana States and Territories list will be complete soon. The Decriminalization list is growing rather large as well...
"Tennessee lawmaker looks to legalize medical cannabis next legislative session":
Oct 3, 2022
https://whnt.com/news/tennessee-news/tennessee-lawmaker-looks-to-legalize-medical-cannabis-next-legislative-session/
"Kentucky Governor Unveils Medical Marijuana Committee Findings, Including Straw Poll Showing 99 Percent Support For Reform":
September 30, 2022
https://www.marijuanamoment.net/kentucky-governor-unveils-medical-marijuana-committee-findings-including-straw-poll-showing-99-percent-support-for-reform/
"States/Territories with Medical Marijuana Laws":
Alaska Alabama Arizona
Arkansas California CNMI
Colorado Connecticut Delaware
District of Columbia Florida Guam
Hawaii Illinois Louisiana
Maine Maryland Massachusetts
Michigan Minnesota Mississippi
Missouri Montana Nevada
New Hampshire New Jersey New Mexico
New York North Dakota Ohio
Oklahoma Oregon Pennsylvania
Puerto Rico Rhode Island South Dakota
Utah Vermont Virginia
Virgin Islands Washington West Virginia
Alaska* California* Colorado*
Connecticut* Delaware District of Columbia*
Hawaii Illinois* Louisiana**
Maine* Maryland Massachusetts*
Minnesota** Mississippi Missouri**
Nebraska Nevada* New Hampshire
New Mexico* New York* North Carolina**
North Dakota** Ohio** Oregon*
Rhode Island Vermont* Virginia*
* These jurisdictions have subsequently approved legislation legalizing the adult use and personal cultivation of cannabis.
** These states have partially decriminalized certain marijuana possession offenses. Although the law still classifies marijuana possession offenses as criminal, the offenses do not carry any threat of jail time.
I'm not into synthetic cannabinoids, and have never tried any semi-synthetic cannabinoids, but HHC is naturally occurring. It gave a mild body buzz and kinda made the ol knees and elbows loosen up. I'll report back after a better experiment.
Took a break from flowers and vaped last night instead for the first time in quite a while and it was actually a treat. I've always been a big fan of live resin, but felt like vaping oils was always a bit weaker in taste and effect than quality flowers. However, the tech and quality have come quite a ways, and it was very tasty and potent. Two thumbs up. I also tried the new cannabinoid, HHC, Hexahydrocannabinol, in an edible, and I wanna try it again by itself to really hone in on what's to it, but it did feel pretty nice and actually kind of energetic. The wider variety of cannabinoids in cannabis, including undiscovered ones, will ensure cannabis is a lively and interesting market for a long time to come...
https://en.wikipedia.org/wiki/Hexahydrocannabinol
https://vaping360.com/learn/hhc/
Of course, the industry is already onto an even newer cannabinoid now, HHC-O, which is more potent that HHC...
https://theislandnow.com/blog-112/what-is-hhc-o/
So many new ones on the way...what will the cannabinoid market look like in the next few years?...
"The Newest Cannabinoids to Look Out for in 2022":
September 29, 2022
The Hottest Cannabinoids You Should Look Out for in 2022
HHC-A
HHC-A (hexahydrocannabonolic acid) is a semi-synthetic cannabinoid and a hydrogenated form of THCA (tetrahydrocannabinolic acid). Hydrogenating THCA and converting it into HHCA is a complex process. Producers take isolated THCA, treat it with hydrogen, and expose it to a catalyst such as nickel or platinum. Hydrogenation improves compound stability and thermo-oxidative breakdown resistance.
Studies on HHCA’s effects in mice are promising. HHCA reduced tumor size in mice test subjects by 39.70% compared to THCA, which reduced tumor size by 37.67%.
HHC-O
HHC-O is a very new cannabinoid and one you’ve likely never heard of before. It’s a semi-synthetic cannabis compound and an acetylated form of HHC, which is a hydrogenated version of THC. Producers make HHC-O by combining naturally sourced HHC with acetic anhydride and a nickel or platinum catalyst. Acetic anhydride is a chemical compound that facilitates greater CB1 binding affinity, thus leading to an equally greater euphoric high.
Some producers claim HHC-O is 1.5 to three times stronger than HHC. However, HHC-O users believe it’s far more potent, especially when vaporized. Some Reddit users recommend mixing HHC-O with CBD to counteract the high and induce more relaxation.
Find HHC-O products at Binoid
HHC-P
HHC-P is short for hexahydrocannabiphorol, an intoxicating semi-synthetic cannabinoid and a hydrogenated form of THCP. It’s incredibly stable and highly resistant to heat and UV light, boasting a long shelf life and little deterioration over long periods.
Marketers boldly declare that HHCP products are up to 30-times more potent than delta-9, boasting higher bioavailability and a longer-lasting euphoric high, which is purely anecdotal and not backed by conclusive studies. One article even states it’s 100 to 200-times more potent. Highly doubtful. Users claim HHCP is the strongest cannabinoid currently on the market, outshining THCP and THC-O.
Find HHC-P products at Binoid
CBN-O
CBN-O, also known as CBN-O acetate, is a rare minor cannabinoid belonging to the cannabinol (CBN) cannabinoid family. Like CBN, CBN-O interacts with your endocannabinoid system, specifically your cannabinoid receptors.
Users claim CBN-O is stronger than CBN, typically experiencing euphoric, sedative, and stress-relieving effects. One Reddit user believes CBN-O combats migraines and reduces nausea and anxiety with few after-effects the next morning. Another Redditor explains how CBN-O dosing is a “lifesaver” for THC withdrawal, possibly resulting from CBN and CBN-O’s ability to interact with CB1 receptors. Most CBN-O products are in distillate or isolate form. Distillates are thick, gooey substances like honey, while isolates are crystal-like substances similar to powdered sugar. Both are potent and potentially great for moderate pain and stress symptoms.
Find CBN-O products at Vivimu
THCP-O
THCP-O is short for tetrahydrocannabiphorol acetate. It’s a semi-synthetic cannabinoid and the acetated form of THCP. Thanks to its seven-link carbon chain and “-O” functional group, THCPO is powerfully intoxicating and psychoactive, and users can experience a euphoric high that’s considerably more potent than delta-8 and delta-9. A YouTuber recently vaporized 5% THCP-O with 34% HHC, 28% delta-8, 24% CBG, and 9% CBD and experienced a euphoric high for almost ten hours. Therefore, THCP and THCPO are not suitable for beginners. However, THCPO products might be good for pain relief and sleep support in more experienced cannabis users.
Find THCP-O products at Vivimu
THCb
THCb (tetrahydocannabutol, ?9-Tetrahydrocannabutol, tetrahydrocannabinol-C4) is an intoxicating minor cannabinoid and a homologue of delta-9 THC naturally present in cannabis. The main difference between the two is that THCb has a butyl side chain, while THC has a pentyl side chain. THCb has a better binding affinity at CB1 receptors than THC, but almost equal affinity at CB2 receptors.
Unverified reports claim THCb is 13-times stronger than delta-9 and over 20-times more potent than delta-8. Research suggests THCb is a possible pain reliever and anti-inflammatory.
Find THC-B products at Binoid
THCjd
THCjd (tetrahydrocannabioctyl) is a rare octyl cannabinoid and THC isomer naturally present in cannabis. An octyl cannabinoid means it has an alkyl side chain composed of eight carbon atoms, leading many to believe it’s roughly 19-times more potent than delta-9, which is scientifically unverified but most likely true. Research shows that a cannabinoid requires a side chain of at least three carbon atoms to bind to CB1 receptors; the optimal number is five. Anything higher and it becomes better at CB1 binding (generally), thus leading to a more intense and noticeable high not suitable for beginners.
Users claim mild THCjd doses can promote relaxation and pain relief, but there’s a risk of heightened anxiety and paranoia in higher doses.
Find THCjd products at Delta Extrax
THC-H
THC-H, short for tetrahydrocannabihexol and more formally known as ?9-THCH, is a naturally-occurring cannabinoid and hexyl homolog of delta-9 THC. It was officially discovered in the cannabis plant at the same time as THCP, CBDP, and CBDH in 2019. However, scientists invented a synthetic THCH equivalent called parahexyl back in 1949, which was used by doctors as an anti-anxiety treatment in the mid-20th century. Parahexyl is an illegal substance under the US Controlled Substances Act, but naturally-occurring THCh is likely legal under the Agricultural Improvement Act (2018 Farm Bill).
Find THC-H products at Binoid
$CWBHF daily chart breaking out...
Daily
https://schrts.co/spuqWATj
Weekly
https://schrts.co/UrMcAQwu
$CWBHF News- "Charlotte's Web Full Spectrum Hemp CBD Products Launching Nationwide on Gopuff":
Oct 04, 2022
Gopuff got big—$15 billion big, per its latest valuation—providing on-demand deliveries for more than 4,000 products, including cleaning and home products, medicine, pet care, office supplies, beauty and wellness products, baby products, food, drinks and alcohol. Founded in 2013 by Forbes Under 30 alumni Ilishayev and Yakir Gola, it currently serves more than a thousand cities and employs more than 7,000 people.
Now, customers can order products such as pain, allergy, cold and flu relief, sleep aid products and at-home diagnostic kits through the company’s in-house label, Goodnow. More products including electrolyte drinks, bandages and antihistamines will roll out in coming months.
I’m just messing with you man… Lol I will look into it! ??
To clarify the "no dilution" claim for $CWBHF...their "ATM program" caused dilution in 2021, but as of June 2022, all of those shares have entered the float, as you can see by the float almost equaling the OS at the end of Q2. They can't turn any ATM program back on until at least Jan 3, 2023, so it should be smooth sailing for quite a while. Even then, I believe any new shares issued in 2023 would take six months to hit the float per rule 144.
The Company filed the final short-form base shelf prospectus on May 5, 2021 with Canadian regulators, with a term of 25-
months, which allowed the Company to qualify the distribution by way of prospectus in Canada of up to C$350,000 of common
shares, preferred shares, warrants, subscription receipts, units, or any combination thereof. The final short form base prospectus
expires on June 6, 2023. The Company filed a prospectus supplement to distribute up to C$60,000 of common shares of the
Company (the "Offered Shares") under the at-the-market equity program ("ATM Program"). As of January 4, 2022, the ATM
Program ceased to be available to the Company. The Company could reestablish this ATM once it becomes eligible for shortform registration on Form S-3, which could be as early as January 2023.
Yahoo shows a more current number for the float...and it is also trading at only 50% of it's book value...
Float 142.83M
Book Value Per Share (mrq) 0.80
Hey Neo, I hope all is well. I do hear you. I've never used Uranium but have owned some of those stocks too lol. I'll keep an eye on $EDXC for more moves. Consider some $CWBHF. Volume is very low, but they are the CBD market leader by revenue, and are at all time low prices. Very low float and market cap less than revenues. No dilution at all, and none is on schedule. OS has been 145mil all year...
https://www.otcmarkets.com/stock/CWBHF/security
https://mjbizdaily.com/top-cbd-companies-experience-market-share-drop-as-online-sales-soften/
Morning Darth,
Hey you don't need to necessarily use the product to own the stock. Their vape product is a zero-nicotine based innovation now acquired through a recent acquisition of Hyla. They also have many CBD products in distribution and a high end skincare line that is now getting international penetration through Amazon. The CEO is showing noteworthy progress in capturing multiple and rapidly expanding markets simultaneously.
They have major name recognition in the cannabis space and with major political shifts coming once the CSA is overturned, they're positioned perfectly (given their low float status and attractive price) to see a massive move in the months ahead.
I am predicting dollarland coming during this trading season.
Enjoy your Saturday,
Neo
Ah, I see they have a pet line and topicals etc. Ok, good talk lol. Tis the season or should be soon.
Nice move on $EDXC today. I've owned some of that one a few times in the past. I don't have anything against them, but I'm just not into vaping. I like glass+flowers, tinctures, gummies, topicals, etc. Are they only doing vapes these days, or the other stuff too?
Lol, well, hopefully we don't need him to actually do anything. Tide could be turning for CBD. We should hopefully have a bullish cannabis season sometime soon...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170084512
The President wouldn't lie about legalization, would he?
Endexx Corp. - EDXC's recently acquired (controlling-interest) HYLA division, secures two major purchase orders for its new innovative vape-delivery product that holds 4500 puffs per built-in cartridge unit. The combined orders represent a 150,000-unit order and a 52,000-unit order for over 200,000 units within the first month of the acquisition of Hyla.
Seems like acquiring Hyla was a great decision for Endexx, already seeing the results! This will be a catalyst for growth.
https://seekingalpha.com/news/3886308-endexx-s-hyla-division-secures-two-purchase-orders-exceeding-200000-units
$CWBHF-"Charlotte's Web Signs Distribution Agreement with Southern Glazer's Wine & Spirits":
SEPTEMBER 26, 2022
Charlotte's Web Full Spectrum CBD Hemp Extracts Coming to Leading U.S. Spirits Distributor
DENVER, Sept. 26, 2022 /CNW/ - (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in hemp-derived cannabidiol ("CBD') extract wellness products, has signed a multi-year distribution agreement with Southern Glazer's Wine & Spirits ("Southern Glazer's"), the world's premier distributor of wine and spirits. Charlotte's Web CBD gummies, capsules and oil tinctures will be available through Southern Glazer's retail customer network.
Charlotte’s Web Signs Distribution Agreement with Southern Glazer’s Wine & Spirits for its Full Spectrum CBD Hemp Extracts (CNW Group/Charlotte's Web Holdings, Inc.)
Charlotte's Web is known for producing The World's Most Trusted Hemp ExtractTM. This distribution agreement brings together America's leading CBD brand with America's leading wine and spirits beverage distribution company. Southern Glazer's operations in 44 U.S. states and the District of Columbia reach consumers at mainstream retail stores licensed to sell alcohol including grocery and specialty retailers.
"This exciting relationship is another step in delivering on our promise to shift our model to key multi-state distributor relationships in new industry verticals," said Jacques Tortoroli, Chief Executive Officer of Charlotte's Web. "Southern Glazer's large-scale distribution within food and beverage, specialty beer, wine and spirits retail, hospitality and big box retail addresses consumer demand for wellness options in this category. I look forward to working closely to grow our respective businesses."
"We've continued to build on our expertise in CBD by providing our suppliers and customers with a trusted distribution experience that enables us to grow this category," said Kariff Rhooms, Vice President, New Ventures, Southern Glazer's Wine & Spirits. "Adding Charlotte's Web enables us to bring an expanded portfolio of innovative products to our retail customers and continue to grow the exciting CBD category."
Subscribe to Charlotte's Web investor news.
About Southern Glazer's Wine & Spirits
Southern Glazer's Wine & Spirits is the world's preeminent distributor of beverage alcohol, and proud to be a multi-generational, family-owned company. The Company has operations in 44 U.S. states, the District of Columbia, and Canada. In 2021, Southern Glazer's was selected as a U.S. Best Managed Company by Deloitte Private and The Wall Street Journal, as well as named by Newsweek as a Top 100 Most Loved Workplace. Southern Glazer's urges all retail customers and adult consumers to market, sell, serve, and enjoy its products responsibly. For more information visit www.southernglazers.com. Follow us on Twitter and Instagram @sgwinespirits and on Facebook at Facebook.com/SouthernGlazers.
About Charlotte's Web Holdings, Inc.
Charlotte's Web Holdings, Inc., a Certified B Corporation headquartered in Denver, is the market leader in innovative hemp extract wellness products under a family of brands which includes Charlotte's Web™, CBD Medic™, CBD Clinic™, and Harmony Hemp™. Charlotte's Web branded premium quality products start with proprietary hemp genetics that are 100-percent American farm-grown using organic cultivation practices. The Company's hemp extracts have naturally occurring botanical compounds including cannabidiol ("CBD"), CBC, CBG, terpenes, flavonoids, and other beneficial compounds. hemp compounds. Charlotte's Web product categories include full-spectrum hemp CBD oil tinctures (liquid products), CBD gummies (sleep, stress, exercise recovery), CBD capsules, CBD topical creams and lotions, as well as CBD pet products for dogs. Charlotte's Web products are distributed to more than 15,000 retail, over 8,000 health care practitioners, and online through the Company's website at www.CharlottesWeb.com.
EDXC
Back on the radar making a strong move from .04 to .08's in one week. A test of a dime could trigger a broader move ahead of a gathering uplisting to OTC level from pink current.
Loading below a dime is a strong investment IMO.
Best,
Neo
#27 or #28, I don't know. Either way, I thought I already gave you a follow a while back, but have now. FDA has ruined the market, not just because of CBD, but so many plays these days just boil down to stocks needing the FDA to say "ok, your stock can go up now." I'm over it.
After CBD is sorted out, I will never put money into a play that is dependent upon the FDA ever again. As soon as THC is rescheduled, the FDA will get to dick with that too. They need to be held accountable for their criminal scumbaggery with the jabs, cannabinoids, baby formula shortages, insulin shortages, cancerous baby powder, and all the crap they allow into our food supply to purposely poison us. One example is how High Fructose Corn Syrup is a pro-inflammatory that severely damages testicles over time, and the FDA knows this, but HFCS is still deemed GRAS. FYI, melatonin can reverse the damage, but the FDA should require Coke, Dr. Pepper, etc to put that on their labels. Ah, but anti-inflammatory CBD is sooo much more dangerous. Bullshit. Our own institutions have been weaponized against us for a long time now. Gotta take them back under responsible control or tear them down now.
"The effects of high-fructose corn syrup consumption on testis physiopathology-The ameliorative role of melatonin":
2019 Jun 5
https://pubmed.ncbi.nlm.nih.gov/31168831/
#27 or #28, I don't know. Either way, I thought I already gave you a follow a while back, but have now. FDA has ruined the market, not just because of CBD, but so many plays these days just boil down to stocks needing the FDA to say "ok, your stock can go up now." I'm over it.
After CBD is sorted out, I will never put money into a play that is dependent upon the FDA ever again. As soon as THC is rescheduled, the FDA will get to dick with that too. They need to be held accountable for their criminal scumbaggery with the jabs, cannabinoids, baby formula, insulin shortages, and all the crap they allow into our food supply to purposely poison us. One example is how High Fructose Corn Syrup is a pro-inflammatory that severely damages testicles over time, and the FDA knows this, but HFCS is still deemed GRAS. FYI, melatonin can reverse the damage, but the FDA should require Coke, Dr. Pepper, etc to put that on their labels. Ah, but anti-inflammatory CBD is sooo much more dangerous. Bullshit. Our own institutions have been weaponized against us for a long time now. Gotta take them back under responsible control or tear them down now.
"The effects of high-fructose corn syrup consumption on testis physiopathology-The ameliorative role of melatonin":
2019 Jun 5
https://pubmed.ncbi.nlm.nih.gov/31168831/
Thanks IH. #28 for you..."GOP Lawmakers Blast FDA Over Lack Of CBD Regulations And Demand Status Update":
33 mins ago on September 22, 2022
https://www.marijuanamoment.net/gop-lawmakers-blast-fda-over-lack-of-cbd-regulations-and-demand-status-update/
Could get interesting...
"Traders Across the World Rush to Close Bets Ahead of Fed Decision":
September 21, 2022
Investors should close short positions on bonds, stocks
Followers
|
729
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
21475
|
Created
|
12/11/09
|
Type
|
Free
|
Moderator neophyte184 | |||
Assistants Rich MoMoney4me1 Art Vandeley OhManIDied Hunchbackgeek $Pistol Pete$ |
Posts Today
|
0
|
Posts (Total)
|
21475
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |